Interval Between Colonoscopies May Be Lengthened For Some Colorectal Cancer Patients, Ochsner Study Concludes

Publication
Article
OncologyONCOLOGY Vol 10 No 8
Volume 10
Issue 8

The interval between follow-up colonoscopies may be increased from 1 to 3 years for colorectal cancer patients whose examinations are negative after 2 years, concludes a study of 389 patients at the Ochsner Clinic, New Orleans, Louisianna,

The interval between follow-up colonoscopies may be increasedfrom 1 to 3 years for colorectal cancer patients whose examinationsare negative after 2 years, concludes a study of 389 patientsat the Ochsner Clinic, New Orleans, Louisianna, reported inDiseases of the Colon & Rectum (DC&R).

"We believe this recommendation outlines appropriate andcost-effective colon surveillance guidelines for colorectal cancerpatients and will help decrease the total number of normal surveillanceexaminations," write Ochnser's Douglas A. Khoury, MD, FrankG. Opelka, MD, David E. Beck, MD, Terry C. Hicks, MD, Alan E.Timmcke, MD, and J. Byron Gathright, Jr., MD.

Current guidelines of the American Society of Colon and RectalSurgeons (ASCRS) recommend annual colonoscopies for up to 5 yearsafter a patient has surgery for colorectal cancer.

Reoperation Plus Surgery for Local Recurrence of Recal Carcinoma

Another study reported in the March issue of DC&R offers increasedhope for patients who experience a local recurrence of cancerafter surgery for rectal cancer. "In selected patients withlocal recurrence of rectal carcinoma, reoperation with irradiationmay result in good palliation and possibly cure," reportTheoWiggers, MD, PhD, Mark R. de Vries, MD, and Bernadette Veeze-Kuypers,MD, of the Departments of Surgical Oncology and Radiotherapy atDr. Daniël den Hoed Cancer Center in Rotterdam, The Netherlands.

Surgery is the most effective treatment for colorectal cancer.Even when all visible cancer has been removed, it is possiblefor cancer cells to be present in other areas of the body. Thechance of recurrence depends on the characteristics of the originalcancer and the effectiveness of chemotherapy or radiation, ifneeded, or other follow-up treatment. Patients with recurrentcancers--if diagnosed early--may benefit, or be cured, by furthersurgery or other treatment.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content